Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prizloncabtagene autoleucel - AbelZeta Pharma

Next Previous
X
Search
Drug Profile

Prizloncabtagene autoleucel - AbelZeta Pharma

Alternative Names: Anti-CD19 anti-CD20 bispecific chimeric antigen receptor T cell therapy - AbelZeta Pharma; Anti-CD20-Anti CD19-BICAR - AbelZeta Pharma; Autologous second generation CD19/CD20-directed CAR-T cells; C-CAR039; CD19/CD20-directed CAR-T cells; EXP0-039; EXP039; JNJ-4496; JNJ-90014496; Prizlon-cel - AbelZeta Pharma

Latest Information Update: 21 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group
  • Developer AbelZeta Pharma; Janssen Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action CD137 antigen agonists; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 28 Mar 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Australia (IV) (NCT05421663)
  • 14 Dec 2023 Phase-I clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV) before December 2023
  • 14 Dec 2023 Janssen receives IND approval from The Centre for Drug Evaluation in China for C CAR 039

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top